A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Status:
Terminated
Trial end date:
2021-09-10
Target enrollment:
Participant gender:
Summary
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex
for production of human IL-12. IL-12 is a protein that can improve the body's natural
response to disease by enhancing the ability of the immune system to kill tumor cells and may
interfere with blood flow to the tumor.
The main purpose of this study is to evaluate the safety and tolerability of a single tumor
injection of Ad-RTS-hIL-12 given with oral veledimex in the pediatric population.